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Arylamines, nitroarenes, and azo dyes yield a common type of metabolite, the nitrosoarene, which produces a
hydrolyzableadductwithproteinandisdosely relatedtothecritical,ultimatetoxicandgenotoxc metabolite. Thetarget
dose as measuredby hemoglobinadducts inerythrocytes reflects notonly theactual uptakefromtheenvironment but
alsoanindividual'scapacity formetabolic activationandisthereforeanimproveddosimeterforhumanexposure. The
usefulnessofhemoglobinadductsinmolecularepidemiologyisnowwidelyrecognized. Withregardtoriskassessment,
many questionsneedto beanswered. Thedescribedexperiments inratsaddresssomeofthesequestions. The relation-
ship between binding to hemoglobin inerythrocytesandto proteins in plasma hasbeenfoundtovaryconsiderably for
anumberofdiamines. The fractionofhydrolyzableadductsoutofthetotalproteinadductsformedalsovaries in both
compartments. This indicatesthat thekind ofcirculating metabolites andtheiravailability indifferentcompartments
is compound specific. This has to do with the complex pattern ofcompeting metabolic pathways, and the role ofN-
acetylation anddeacetylation isemphasized. Anexampleofnonlineardosedependenceaddstothecompleity. Analysis
ofhemoglobinadductsrevealsinterestingiightsintopreilingpathways,whichnotonlyapplytothechemical, butmay
also be useful to assess an individual's metabolic properties. In addition, it is demonstrated that the greater part of
erythrocytesand benzidine-hemoglobin adducts areeliminated randomly in rats, i.e., followingfirst-orderkinetics.
Binding of N-Substituted Arenes to
Blood Proteins
Since ourfirststudy onbindingofarylamines tobloodproteins
(1) and the proposal thathydrolyzable sulfinic acid amides are
formedby the reactionofnitrosoderivatives withthesulflhydryl
group ofcysteine (2), we have investigated quite a number of
chemicals inthe rat (3-7). In most casesunlabeledcompounds
were usedandhemoglobin (Hb) binding was ofprimary interest,
so only the hydrolyzable fraction ofhemoglobin adducts was
reported. Occasionally, radiolabeled chemicals were available
and enabled us toask someadditional questions that arerelevant
to assessthepotential ofusingbloodproteinbindingdataforrisk
assessment. One aspect usually concerns the relationship be-
tween theprotein targetdose inerythrocytes andthetissuedose
in liver andextrahepatic tissues. Aclueto thiscomplex problem
may beobtainedby comparing hemoglobinbindingwithbinding
toplasmaproteins. Additional information maybeobtainedfrom
the comparison ofthe hydrolyzable fractions ofthe adducts in
both compartments. Some data are compiled in Table 1.
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ThedatainTable 1 arearrangedintheorderofthehemoglobin
binding index (HBI), whichcorrects forthedifferentdoses used
and isdefined as mmole/mole Hb/dose (mmole/kg). A plasma
protein binding index (PPBI) is used accordingly. As demon-
strated previously (4,8), the fraction ofthe administered dose
thatbinds tohemoglobinvariesoverawiderange. Withthe ex-
ceptionof3,3'-dichlorobenzidine, mostofthehemoglobinbind-
ingisattributabletothehydrolyzablesulfinicacidamideadduct
(70-90%), whichindicatesthatreactivemetabolitesotherthan
thenitrosoarenes arenotavailableintheerythrocytestoagreat
extent. Binding to plasma proteins is highly variable, i.e.,
specificbindingmaybeinthe samerangeastohemoglobin, or
significantlylowerorhigherthanthat(ratioHb:PP). Moreover,
nonhydrolyzable adductsofunknownorigin dominate.
Some points are notable. Nitrosobenzene is the exclusive
adduct-forming metaboliteofnitrobenzene inerythrocytes but
seemstobealsoreadilyavailableinplasma(hydrolyzablefrac-
tion 98 and 59%, respectively). Protein-binding metabolites
other than nitrosobenzene are available in plasma with acet-
anilide, possibly derived from p-hydroxy-acetanilid
(hydrolyzable fraction 16% as compared to 59% with
nitrobenzene). 4-Chloroanilinebindsextremely well to hemo-
globin. Thenitrosoderivative seemstobeformedpredominantly
withintheerythrocyte, andnotmuchofitisavailableinplasma
(ratioHb:PP = 29). Thedifferencesbetweenbenzidineand3,
3'-dichlorobenzidine arealsonoteworthy. Inbothcasesmetabo-NEUMANNETAL.
Table 1. Total binding ofN-substituted arenes to blood proteins 24 hr after oral administration ofthe labeled compounds and the hydrolyzable fraction.
Binding to
Dose, Hemoglobin Plasmaproteins Ratio binding
Compound administered /Amole/kg HBI Hydrolyzable % PPBI Hydrolyzable % Hb:PP
4-Chloroaniline 14 162 93 5.5 24 29.3
trans-4-Acetylaminostilbene 29 157 73 70 5 2.2
Nitrobenzene 200 73 95 9.3 58 7.6
Benzidine 1.1 56 84 111 ND 0.5
Acetanilid 150 12 88 4.8 16 2.5
3,3'-Dichlorobenzidine 50 6 32 36 26 0.2
Abbreviations: HBI, hemoglobin binding index; PPBI, plasma protein binding index; Hb, hemoglobin; PP, plasma protein; ND, not determined.
litesbindmoreextensivelytoplasmaproteinsthantohemoglobin
(ratio Hb:PP 0.5 and 0.2, respectively). With 3,3 '-
dichlorobenzidine, anitrosoderivativecontributes significant-
ly to binding in plasma.
It may be inappropriate to try to correlate such findings with
carcinogenicity atthepresenttimefortworeasons: first, adirect
comparison of the carcinogenic potency in Wistar rats is not
available; second, thedatademonstratethatformation, distribu-
tionand, asaconsequence, thetargetdoseofreactivemetabolites
do not seemtobepredictable frommeasuring aparticularadduct
inerythrocytes incaseofN-substituted arenes. Itremains tobe
furtherelucidated whetherbetterconclusions canbedrawnabout
the targetdoseinextrahepatic tissues whenbothproteinbinding
in plasma and in erythrocytes are considered.
Elimination of Hemoglobin Adducts
Tocorrelateprotein binding datawithgenotoxic targetdoses,
itis also necessary toconsiderthestability ofadductsandtheir
elimination kinetics. There is some confusion in the literature
because theterm "elimination half-life" is notconsistent with a
definite life spanoferythrocytes. Iferythrocytes areeliminated
according tooldage, theirelimination ratetogetherwiththatof
Hb adducts should follow zero-order kinetics. However, ex-
ponential eliminationofadductshasbeendescribedandconse-
quently associated withchemical instability oftheadducts (9).
We previously described an exponential elimination ofHb-
benzidine adducts in rats with a half-life (t,,) of 11.5 days (10)
and studied this problem recently in more detail (11). For this
purpose, erythrocytes were labeledby injecting [3H]diisopropyl-
fluorophosphate (DFP) into 18femaleWistarrats. Theanimals
were divided into two groups after 3 days; one received [14C]-
benzidine by gavage (2.5 .tmole/kg), the other one served as a
solvent control. Radioactivity ofwashederythrocytes wasdeter-
mined five times up to 28 days after administration. From the
semilogarithmic plot, an exponential decrease was delineated
with t1,2 = 14.4 and 14.7 days, respectively, for the DFP label
andt1,2 =14.4days for thebenzidine label.
Theexperimentwas repeatedwith52animals (2foreachtime
point) over44days. Althoughalinearregressioncouldhavebeen
calculated with asatisfying correlationcoefficient, thisdid not
seem tobeacceptable becauseatrendtowardadecreasingslope
forbenzidinebinding fromearly overmiddle tolatetimepoints
wasevidentinthelinearplot. Inthesemilogarithmicplot, onthe
other hand, it turned out that the slope became steeper for the
period from27 to 44days. Iftherelationship recommendedby
theInternational Committee for Standardardization inHaema-
tology (12)
e(-kt) e-kl) (-e )
(k = fractionoferythrocytes eliminated perday independentof
age; T= lifespanoferythrocytes;N0 = numberoferythrocytes
at time 0).
wasusedtofitthedata, thevaluesforkand Tcouldbecalculated.
According to this equation, the upper limit ofthe life span of
erythrocytesinthese ratsis65 days, butinaddition 3% perday
oftheerythrocytes areeliminatedindependentofage. This im-
plies that two processes take place independently and that the
elimination rate is satisfactorily described by an exponential
function (tl/2) up to 40 days. Also, in the second experiment
described above, the benzidine label (t1/2 = 16.5 days) and the
DFP label (t1,2 = 18 days) of washed erythrocytes were
eliminated with the same rate.
Theelimination rateoferythrocytesinratshasbeenmeasured
bymanyauthorsandwithdifferentmethods. Labelingwith 59Fe
5'Cr, 32P[DFP], and [14C]glycine was used. Average life spans
from40to 100dayswerereported. Insomemorerecentpublica-
tions (13-16), elimination was measured up to 20 days, semi-
logarithmicplotswereused, andfirst-orderkineticswereassum-
ed. Ourvalues are ingoodagreementwiththose reported: 18.7
(15), 14.6 (16), and 13.5 days (17).
In summary, incontrastto mouseandman, randomdestruc-
tionoferythrocytes is faster in the rat, and the elimination can
bestbedescribedinitiallyby anexponential function. Theresults
demonstratethatbenzidinetreatmentdoesnotaltertheelimina-
tionrateoferythrocytes. Inaddition, asignificant differencebe-
tween the elimination rates oferythrocytes and theHb adducts
could not be demonstrated. The benzidine adduct is therefore
considered stable in vivo.
Hemoglobin BindingofDiaminoarenes
Hemoglobin adduct levels vary widely between individuals.
Thismaybepartlyduetodifferences inmetabolicactivation. N-
Acetylation may play a particular role because notable dif-
ferences occurbetweenrapidandslowacetylators(18). Such a
rolebecameparticularly apparentwhenwestudiedHbbinding
ofbifunctional N-substituted arenes in rats. Hydrolysis ofthe
sulfinicacidamideadductyieldsproductsinwhichthenonbind-
ingnitrogenmay eitherbeacetylatedornonacetylated. Surpris-
ing differences were observed in thisrelationship (Table 2).
Benzidine is predominately activated by N-oxidation of the
monoacetylated diamine. This is indicated by the ratio for the
cleavage products diamine:monoacetyldiamine of 1:10. With
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Table 2.Henmglobin bindingofbifunctional arylamines 24 hrafter oraladministration tofemaleWistarratsand thecleavage products obtained
afterhydrolysis ofthe adducts.
Cleavageproducts
Compound administered Dose, mmole/kg HBI Diamine Monoacetyldiamine Ratio
Benzidine 0.5 21.3 2.4 18.9 0.1
3,3'-Dichlorobenzidine 0.5 3.5 2.0 1.5 1.3
3,3'-Dimethylbenzidine 0.5 2.9 1.9 1.0 1.9
3,3'-Dimethoxybenzidine 0.5 2.7 2.6 0.1 26.0
4,4'-Ethylenedianiline 0.5 18.1 14.7 3.4 4.3
4,4'-Oxydianiline 0.5 16.8 10.4 6.2 1.7
4,4'-Methylene-bis-2-chloroaniline 0.5 5.1 5.1 ND -
4,4'-Methylenedianiline 0.5 3.7 3.1 0.6 5.2
0.07 4.2 2.5 1.7 1.5
2,4-Diaminotoluene 0.25 ND
10 x 0.1 (19days) ND
2,6-Diaminotoluene 0.25 0.2 ND 0.2 -
10 x 0.1 (19days) 0.4 ND 0.4
ND, not detected.
3,3'-dimethoxybenzidine, totalbinding islowerbutthisratiois
quitedifferent (26:1). With 4,4'-methylene-bis-2-chloroaniline
(MOCA), theacetylateddiaminecouldnotbedetectedatall. The
other bridged derivatives (Table 2) form predominantly non-
acetylated adducts. In contrast, the two isomeric diaminoto-
luenes seem to be activated only in the acetylated form.
Implications forriskassessmentcanbe seenwithbenzidine.
Benzidine is not a substrate for cytochrome P-450 or flavin
monooxygenase (19). However, itcanbeoxidizedbyperoxidases
tobenzidinediimine, which isabletoreactwith DNA(20). As
a monoacetyl derivative, on the other hand, benzidine is a
substrate forcytochromeP-450, andasingleN-acetylation has
beenconsideredessentialforthecriticalactivatingpathway (21).
Benzidine and the three 3,3'-disubstituted congeners (Table2)
areclassifiedascarcinogenic (22), butadirectcomparisonofthe
carcinogenic potency is not available. Mutagenicity has been
compared inSalmonellatyphimurium. Inbothstrains, TA98and
TA100, mutagenicity decreased in the order 3,3 '-dichloro-
benzidine > 3,3'-dimethoxybenzidine > benzidine (23). The
HBIwould suggestquiteanother sequenceofpotency, withben-
zidineyieldingthehighestgenotoxictargetdose. Consideringthe
differences inmetabolicactivation inthebacterial system even
inthepresenceofliverenzymesandtheinvivosituation, itseems
plausible that the HBI reflects the presence of genotoxic
metabolites in vivo betterthan the mutagenicity data.
AnotheraspectthatmayhavetodowithN-acetylationequil-
ibria is the dose dependence ofmetabolic activation. We have
studied the dose dependence of Hb binding of 3,3'-
dichlorobenzidine, whichis releasedfrommany industrial azo
dyes after azo reduction, and observed significant deviations
from a dose-proportionate increase (Fig. 1). The HBI for the
hydrolyzable fraction increases from0.5 at low doses to 2.7 at
highdosesinthisstudy. Thisisalmostcompletely duetoanover-
proportionate increaseofthediaminewithinanarrowdoserange
around0.1 mmole/kg. Theratiodiamine:monoacetyldiamine in-
creasesclearly from 3 to 10(Zwirner-BaierandNeumann, un-
published data).
Included inFigure 1 are dataobtained with 4,4'-methylene-
dianiline (MDA) published by Bailey etal. (24). In contrast to
our results for MDA (Table 2), these authors find more ofthe
monoacetylated cleavageproductthanofthediamine, butthey
also observed a relative increase ofthe diamine fraction with
10
0.1
Cleavage products (pmol/mg)
10 100 1000
Dose (iunol/kg)
FIGURE 1. Dosedependenceofhemoglobinbinding. 3,3'-Dichlorobenzidine
(DCB) was orally administered to female Wistar rats. Hemoglobin was
isolated24hrlater, andthetwocleavageproducts obtainedbyhydrolysis were
determinedby HPLC withelectrochemical detection. (A) DCB; (O) mono-
acetyl-DCB. Thedata for(*-*) 4,4'-methylenedianiline (MDA) and (x-x)
monoacetyl-MDA were taken from Bailey et al. (22).
dose(ratiodiamine:monoacetyldiamine from0.1 to0.4). These
data cannot readily be interpreted. Saturation of the N-ace-
tylationcapacity, however, does not seem tobe theexplanation.
Hemoglobin Adducts As Indicators of
Metabolic Activation in Vivo
Dinitrotoluenes are ofgreatpractical importance as starting
material fortheproductionofdiaminotoluenes, which areused
in great quantities as intermediates in the synthesis oftoluene
diisocyanates, components inpolyurethaneproduction. In addi-
tion, bothdinitrotoluenes anddiaminotoluenes arefound inthe
environmentas wasteoftheformerproductionofexplosives. The
I
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Tbble 3. Metabolc pathways andbioavailability ofreactive metabolites asindicated by theformationofhemoglobin adducts.
Cleavageproducts indicating
Compound administered Carcinogenic N-Oxidation only NO2-Reduction Acetylation
2,4-Diaminotoluene + ND ND
2,4-Dinitrotoluene + 4-A-2-NT (0.7)8
2-Amino-4-nitro-toluene + 2,4-DAT (0.9) 2-AA-4-AT (0.1)
2-Nitro-4-amino-toluene ? 2-N-4-AT (0.:)
2,6-Diaminotoluene 2-AA-6-AT (0.2)
2,6-Dinitrotoluene + + 2-A-6-NT (1.0)
2,6-DAT (0.2)
2-Amino-6-nitrotoluene ? 2-A-6-NT (0.4) 2,6-DAT (0.2) 2-AA-6-AT (0.1)
Abbreviations: A, amino; AA, acetylamino; DA, diamino; N, nitro; T, toluene; ND, not detected.
'Hemoglobin binding index in parentheses.
2,4- and 2,6-isomers are most prevalent. Methods for bio-
monitoring are desirable.
Practicallyallaminoandnitroderivatives oftoluenearemu-
tagenic inin vitr testswithsomedifferences inpotency (25-27).
The tests on carcinogenic potential, on the other hand, reveal
striking differences. 2,6-Dinitrotoluene (2,6-DNT) is a strong
carcinogen (28), whereas 2,6-diaminotoluene (2,6-DAT) is
negative (29). 2,4-Dinitrotoluene (2,4-DNT) issignificantly less
carcinogenicthanthe2,6-isomer, andithasevenbeensuspected
thatimpurities withthelattermayexplaintheeffect. Incontrast,
2,4-diaminotoluene (2,4-DAT) iscarcinogenic (30). These fin-
dings lead to the conclusion that expression ofthe genotoxic
potential of these chemicals is markedly influenced by phar-
macokinetic parameters in the complex in vivo situation.
InadditiontothequestionofwhetherHbbindingcanbeused
forexposurecontrol, itwasofinteresttoseewhetherthecleavage
products from Hb adducts tell something about preferential
metabolicpathways. Onlypartsofthemetabolismofthesecom-
pounds areknown. ItisassumedthataN-hydroxy-amino func-
tion has to be formed metabolically for genotoxicity. Thus, an
amino group has to be N-oxidized or a nitro group has to be
reduced to generate a proximate mutagen. Acetylation of an
amino group can be another determinant. Because the
hydrolyzableadductofHbis formedbythereactionofanitroso
group with a sulfhydryl group and releases an amino group,
everycleavageproductcontains atleastoneaminofunctionthat
indicateswhichnitrogenwasinvolvedinmetabolicactivationand
adduct formation.
The results thatwereobtainedbyhydrolyzing Hbadducts24
hrafterfeeding thevariouschemicals tofemaleWistar rats are
summarized in Table 3. Hydrolyzable Hb adducts were found
withall chemicalstested, exceptwith2,4-DAT. TheHBIvalues
arecomparatively low, sotheanalysis ofhumanblood samples
will require extremely sensitive methodology. Inaddition, the
situation iscomplicatedbythecomplexpatternofcleavagepro-
ductsofthesebifunctional substances. Asimplecorrelationbe-
tweencarcinogenicity and Hbbindingcould notbedetected in
thisstudy. Thismaybepartlyduetothefactthatanotherpossibly
relevant metabolic pathway is notcontrolled withthis method:
the oxidation ofthe methyl group. 2,4-Dinitrobenzylalcohol-
glucuronide and2,4-dinitrobenzoic acidaremajormetabolites
of2,4-DNT in rat urine (31). 4-Acetylamino-2-aminobenzoic
acid was described as ametaboliteof2,4-DAT (32). Such a C-
oxidation product, however, was not observed with 2,6-DAT
(33). Analysis ofurinarymetabolites didnotindicatetheforma-
tion of N-oxidation products in both studies with diamino-
toluenes. Because2-acetylamino-6-aminotoluene hasbeen iden-
tifiedafterhydrolysisofHbfrom2,6-DAT-treatedanimals, itis
now evident that N-oxidation occurs in vivo (Table 3). With a
limitedamountof14C-labeled2,4-DATand2,6-DAT(kindlypro-
videdbyM. Cunningham), wewereabletomeasuretotalbinding
toHbandplasmaproteinsaswellastotaltissueconcentrationin
lung,liver,kidney, spleen,andadrenals. With2,6-DAT,allvalues
wereonaverageone-thirdofthoseobtainedwith2,4-DAT, i.e.,
tissue doses are lower with the non-carcinogenic 2,6-DAT
(Zwirner-BaierandNeumann,unpublisheddata). Itisinteresting
tonote, however, thatreactivemetabolitesbindtobloodproteins
withbothchemicals, butwith2,4-DATonlynonhydrolyzable Hb
adducts are formed, andwith2,6-DATonly a small fraction of
theboundmaterialishydrolyzable. Theoriginofnonhydrolyz-
able adducts remains to be studied. Phenolic metabolites are
possibleprecursors inadditiontoN-oxidationproductsandben-
zylic alcohol orbenzaldehydederivatives. One suchmetabolite,
5-hydroxy-2-acetylamino-6-aminotoluene, is mutagenic in S.
typhimurium TA 98 in thepresence ofS9-mix (33).
Nevertheless, someinterestingconclusionscanbedrawnabout
prevalentmetabolicpathways. With2,6-DAT,acetylationofone
aminogroupisaprerequisiteforN-oxidationoftheother. AnN-
oxidationproductof2,4-DATcouldnotbedemonstrated. In2,4-
DNT only the nitro group in thepara position is reduced, al-
though a nitro group ortho to the methyl group is accessible to
reduction. With 2,6-DNTboth nitro groups are reduced. In 2-
amino-4-nitrotoluene, which is also classified as carcinogenic
(22), thepam nitro group is morereadily reducedthanthe or-
tho amino groupoxidized. In2-nitro-4-aminotoluene it is also
thepara substituent that is preferentially metabolized. In the
ortho-disubstituted 2-amino-6-nitrotoluene both functions are
metabolized. Inotherwords, anaminofunctioninorthoposition
to the methyl group can in principle be oxidized as well as
acetylatedinvivo. Anitrogroupcanbereducedinthisposition.
Bothfunctionalgroupsarepreferentiallymetabolizedinthepara
position, regardlessofthesecondsubstituent intheorthoposi-
tion. The results may alsoindicatethatthenitro groups are not
necessarily reduced to the amines before macromolecular
binding.
This manuscript was presented at the Conference on Biomonitoring and
Susceptibility Markers inHumanCancer: Applications inMolecularEpidem-
iology and RiskAssessmentthatwasheld inKailua-Kona, Hawaii, 26October-I
November 1991.
This work was supported by the Deutsche FDrschungsgemeinschaft and the
Commission of the European Community. The technical assistance of Elke
Maurer, Hella Raabe, Elisabeth Riib-Spiegel, and Siglinde Stoll is gratefully
acknowledged.
68HEMOGLOBINADDUCIS OFAMINO- ANDNITROARENES 69
REFERENCES
1. Wieland, E., and Neumann, H.-G. Methemoglobin formation and binding
to blood constituents as indicators for the formation, availability and
reactivity ofactivated metabolites derived fromtrans-4-aminostilbene and
related aromatic amines. Arch. Toxicol. 40: 17-35 (1978).
2. Dolle, B., Topner, W., and Neumann, H.-G. Reactionofaryl-nitrosocom-
pounds with mercaptans. Xenobiotica 10: 527-536 (1980).
3. Albrecht, W., and Neumann, H.-G. Biomonitoring of aniline and nitro-
benzene. Hemoglobinbindinginratsandanalysisofadducts. Arch. Toxicol.
57: 1-5 (1985).
4. Birner, G., and Neumann, H.-G. Biomonitoring of aromatic amines II.
Hemoglobinbindingofsomemonocyclic aromatic amines. Arch. Toxicol.
62: 110-115 (1988).
5. Birner, G., Albrecht, W., and Neumann, H.-G. Biomonitoring ofaromatic
amines IH. Hemoglobinbindingofbenzidineand somebenzidinecongeners.
Arch. Toxicol. 64: 97-102 (1990).
6. Sabbioni, G., and Neumann, H.-G. Biomonitoring ofarylamines: hemo-
globin adducts ofurea andcarbamate pesticides. Carcinogenesis 11: 111-115
(1990).
7. Sabbioni, G., and Neumann, H.-G. Quanitification ofhaemoglobin binding
of4,4'-methylenebis-(2-chloroaniline) (MOCA) in rats. Arch. Toxicol. 64:
451-458 (1990).
8. Neumann, H.-G. Haemoglobin binding in control ofexposure to and risk
assessmentofaromaticamines. In: Methods forDetecting DNADamaging
Agents in Humans (K. Bartsch, K. Hemminki, and I. K. O'Neill, Eds.),
IARC Scientific Publication No. 89, International Agency forResearch on
Cancer, Lyon, 1988, pp. 157-165.
9. Skipper, P. L., and Tannenbaum, S. R. Protein adducts in the molecular
dosimetry ofchemical carcinogens. Carcinogenesis 11: 507-518 (1990).
10. Neumann, H.-G. Dosimetry anddose-response relationships. In: Monitoring
Human Exposure to Carcinogenic and Mutagenic Agents (H. Berlin, M.
Draper, K. Hemminki, and H. Vainio, Eds.), IARC Scientific Publication
No. 59. International Agency for Research on Cancer, Lyon, 1984, pp.
115-126.
11. Kowallik, P. Die EliminationvonErythrozyten undBenzidin-Hamoglobin-
Addukten bei der Ratte. Dissertation. University ofWurzburg, Medical
Faculty, Wurzburg, Germany, 1989.
12. ICSH. International Committee forStandardization in Haematology: recom-
mended method for radioisotope red-cell survival studies. Br. J. Haematol.
45: 659-666 (1980).
13. Hjort, P. F., Paputchis, H., andCheney, B. Labellingofredbloodcellswith
radioactive diisopropylfluoro-phophate (DFP32): evidence for an initial
release oflabel. J. Lab. Clin. Med. 55: 416424 (1960).
14. Wohl, H., and Merskey, C. Anemia in rats on atherogenic diets. Am. J.
Physiol. 206: 765-768 (1964).
15. Noble, N. A., and Rothstein, G. TheDpggene: anintracorpuscular modifier
ofred cell metabolism. Blood 67: 1210-1214(1986).
16. Akahane, K., and Furuhama, K., Inage, F., and Onodera, T. Effects of
malotilate on rat erythrocytes. Jpn. J. Pharmacol. 45: 15-25 (1987).
17. Berlin, N. I., Meyer, L. M., and Lazarus, M. Lifespanofthe ratredblood
cell asdetermined byglycine-2-C'4. Am. J. Physiol. 165: 565-567 (1951).
18. Lewalter, J., and Korallus, U. Blood protein conjugates and acetylation of
aromatic amines. New findings onbiological monitoring. Int. Arch. Occup.
Environ. Health 56: 179-196 (1985).
19. Wise, R. W., Zenser, T. V., Kadlubar, F. F., and Davis, B. B. Metabolic ac-
tivation ofcarcinogenic aromatic amines by dog bladder and kidney pro-
staglandin H Synthase. Cancer Res. 44: 1893-1897 (1984).
20. Yamazoe, Y. Zenser, T. V., Miller, D. W., and Kadlubar, F. F. Mecha-
nismofformationand structural characterization ofDNA adducts derived
from peroxidative activation of benzidine. Carcinogenesis 9: 1635-1641
(1988).
21. Kenelly, J. C., Beland, F. A., Kadlubar, F. F., and Martin, C. N. Binding of
N-acetylbenzidine and N,N'-diacetylbenzidine to hepatic DNA ofrat and
hamster in vivo and in vitro. Carcinogenesis 5: 407-412 (1984).
22. CommissionfortheInvestigationofHealthHazardsofChemicalCompounds
in the Work Area. ListofMaximum Concentrations at theWorkplace and
Biological ToleranceValues forWorking Materials 1990. ReportNo. XXVI,
Deutsche Forschungsgemeinschaft, VCH Verlagsgesellschaft, Weinheim,
Germany.
23. Messerly, E. A., Fekete,J. E., Wade, D. R., andSinsheimer, J. E. Structure-
mutagenicity relationshipsofbenzidine analogues. Environ. Mol. Mutagen.
10: 263-274 (1987).
24. Bailey, E., Brooks, A. G., Bird, I., Farmer, P. B., and Street, B. Monitor-
ing exposure to 4,4'-methylenedianiline by the gas chromatography-mass
spectrometry determinationofadducts tohemoglobin. Anal. Biochem. 190:
175-181 (1990).
25. Parodi, S., Taningher, M., Russo, P., Pala, M., Tamaro, M., and Monti-
Bragadin, C. DNA-damagingactivity invivoandbacterial mutagenicity of
sixteenaromaticaminesandazo-derivatives, asrelatedquantitatively totheir
carcinogenicity. Carcinogenesis 2: 1317-1326 (1981).
26. Spanggord, R. J., Mortelmans, K. E., Griffin, A. F., and Simmon, V. F.
Mutagenicity in Salmonella typhimurium andstructure-activity relationships
ofwastecomponentsemanating fromthemanufactureoftrinitrotoluene. En-
viron. Mutagen. 4: 163-179 (1982).
27. Mori, M. A., Miyahara, T.,Taniguchi, K., Hasegawa, K., Miyagoshi, H.
K. M., and Nagayama, T. Mutagenicity of 2,4-dinitrotoluene and its
metabolites in Salmonella typhimurium. Toxicol. Lett. 13: 1-5 (1982).
28. Leonhard, T. B., Graichen, M. E., andPopp, J. A. Dinitrotoluene isomer-
specifichepatocarcinogenesis inF344rats.J. NatI. CancerInst. 79:1313-1319
(1987).
29. NCI. Bioassay of 2,6-toluenediamine Hydrochloride for Possible Car-
cinogenicity. NCI Carcinogenesis Technical Report Series No. 200. DHEW
Publication No. (NIH)80-1756, National CancerInstitute, Bethesda, MD,
1980.
30. IARC. IARCMonographs, Vol. 16. 2,3-Diaminotoluene. International Agen-
cy for Research on Cancer, Lyon, 1978, pp. 83-91.
31. Rickert, D. E., and Long, R. M. Metabolism and excretion of 2,4-
dinitrotoluene inmaleand femaleFischer-344 ratsafterdifferentdoses. Drug
Metab. Disp. 9: 226-232 (1981).
32. Grantham, P. H., Mohan, L., Benjamin, T., Roller, P. P., Miller, J. R., and
Weisburger, E. K. Comparisonofthe metabolism of2,4-toluenediamine in
rats and mice. J. Environ. Pathol. Toxicol. 3: 149-166 (1980).
33. Cunningham, M. L., Burka, L. T., and Matthews, H. B. Metabolism,
disposition, andmutagenicity of2,6-diaminotoluene, amutagenic noncar-
cinogen. Drug Metab. Disp. 17: 612-617 (1989).